Moderna Merck melanoma vaccine trial

Personalized Melanoma Vaccine Cuts Cancer Recurrence Risk

A late-stage trial showed Moderna and Merck's personalized mRNA vaccine, intismeran, reduced melanoma recurrence and death by 42%.

A late-stage trial of Moderna and Merck's personalized mRNA vaccine, intismeran, demonstrated a 42% reduction in melanoma recurrence or death when used alongside Keytruda immunotherapy. The vaccine, which uses mRNA technology and tumor genomic data, showed a promising safety profile with mild side effects.

NBC News: Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
US Top News and Analysis: Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
BBC: Personalised skin cancer vaccine cuts risk of disease returning in major trial
The New York Times: Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report